ORYZON to Present Clinical Data on LSD1 Inhibitor ORY-1001 at ASH 2016
BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - November 14, 2016) - Oryzon Genomics (MAD: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet …